Moderna, Inc. (MRNA) Q1 2021 Earnings Results

Moderna Beats on EPS, Stock Down 1.4%

Moderna's strong EPS performance indicates effective cost management and profitability. However, the stock reacted negatively, declining by 1.4%, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more comprehensive financial insights in future reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.84	N/A	+39.22%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management highlighted their strong EPS results and ongoing commitment to innovation. However, they did not provide specific revenue guidance.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They emphasized ongoing efforts in vaccine development and distribution.

Moderna Beats on EPS, Stock Down 1.4%

Key numbers

Management commentary

Moderna, Inc.

More earnings this week

Moderna Beats on EPS, Stock Down 1.4%

Key numbers

Management commentary